PRELUDE THERAPEUTICS INC (PRLD) Fundamental Analysis & Valuation

NASDAQ:PRLD • US74065P1012

Current stock price

4.425 USD
+0.74 (+20.24%)
Last:

This PRLD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PRLD Profitability Analysis

1.1 Basic Checks

  • In the past year PRLD has reported negative net income.
  • PRLD had a negative operating cash flow in the past year.
  • PRLD had negative earnings in each of the past 5 years.
  • In the past 5 years PRLD always reported negative operating cash flow.
PRLD Yearly Net Income VS EBIT VS OCF VS FCFPRLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of PRLD (-70.41%) is worse than 64.41% of its industry peers.
  • With a Return On Equity value of -144.96%, PRLD is not doing good in the industry: 62.48% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -70.41%
ROE -144.96%
ROIC N/A
ROA(3y)-62.25%
ROA(5y)-55.14%
ROE(3y)-97.7%
ROE(5y)-78.25%
ROIC(3y)N/A
ROIC(5y)N/A
PRLD Yearly ROA, ROE, ROICPRLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PRLD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRLD Yearly Profit, Operating, Gross MarginsPRLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. PRLD Health Analysis

2.1 Basic Checks

  • PRLD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PRLD has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PRLD has more shares outstanding
  • PRLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRLD Yearly Shares OutstandingPRLD Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
PRLD Yearly Total Debt VS Total AssetsPRLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • PRLD has an Altman-Z score of -6.76. This is a bad value and indicates that PRLD is not financially healthy and even has some risk of bankruptcy.
  • PRLD has a Altman-Z score of -6.76. This is in the lower half of the industry: PRLD underperforms 67.31% of its industry peers.
  • There is no outstanding debt for PRLD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.76
ROIC/WACCN/A
WACC9.21%
PRLD Yearly LT Debt VS Equity VS FCFPRLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • PRLD has a Current Ratio of 1.99. This is a normal value and indicates that PRLD is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.99, PRLD is doing worse than 77.37% of the companies in the same industry.
  • A Quick Ratio of 1.99 indicates that PRLD should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.99, PRLD is not doing good in the industry: 75.63% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.99
PRLD Yearly Current Assets VS Current LiabilitesPRLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. PRLD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.67% over the past year.
  • The Revenue has grown by 73.43% in the past year. This is a very strong growth!
EPS 1Y (TTM)23.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.37%
Revenue 1Y (TTM)73.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%41%

3.2 Future

  • Based on estimates for the next years, PRLD will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.70% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.98%
EPS Next 2Y28.73%
EPS Next 3Y1.68%
EPS Next 5Y9.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRLD Yearly Revenue VS EstimatesPRLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
PRLD Yearly EPS VS EstimatesPRLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. PRLD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PRLD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRLD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRLD Price Earnings VS Forward Price EarningsPRLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRLD Per share dataPRLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.73%
EPS Next 3Y1.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PRLD Dividend Analysis

5.1 Amount

  • PRLD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRLD Fundamentals: All Metrics, Ratios and Statistics

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (4/7/2026, 2:30:36 PM)

4.425

+0.74 (+20.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)05-04
Inst Owners35.29%
Inst Owner Change0%
Ins Owners9.91%
Ins Owner Change0%
Market Cap278.77M
Revenue(TTM)12.14M
Net Income(TTM)-99.50M
Analysts84.44
Price Target5.27 (19.1%)
Short Float %7.02%
Short Ratio7.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-272.96%
Min EPS beat(2)-576.13%
Max EPS beat(2)30.21%
EPS beat(4)3
Avg EPS beat(4)-131.32%
Min EPS beat(4)-576.13%
Max EPS beat(4)30.21%
EPS beat(8)6
Avg EPS beat(8)-60.61%
EPS beat(12)10
Avg EPS beat(12)-34.94%
EPS beat(16)14
Avg EPS beat(16)-24.89%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)29.17%
PT rev (3m)29.17%
EPS NQ rev (1m)-29.73%
EPS NQ rev (3m)-29.73%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.96
P/FCF N/A
P/OCF N/A
P/B 4.06
P/tB 4.06
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.19
BVpS1.09
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.41%
ROE -144.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.25%
ROA(5y)-55.14%
ROE(3y)-97.7%
ROE(5y)-78.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.92%
Cap/Sales 0.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.99
Altman-Z -6.76
F-Score5
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)115.85%
Cap/Depr(5y)165.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.37%
EPS Next Y16.98%
EPS Next 2Y28.73%
EPS Next 3Y1.68%
EPS Next 5Y9.7%
Revenue 1Y (TTM)73.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-62.62%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.28%
OCF growth 3YN/A
OCF growth 5YN/A

PRELUDE THERAPEUTICS INC / PRLD Fundamental Analysis FAQ

What is the fundamental rating for PRLD stock?

ChartMill assigns a fundamental rating of 2 / 10 to PRLD.


Can you provide the valuation status for PRELUDE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to PRELUDE THERAPEUTICS INC (PRLD). This can be considered as Overvalued.


How profitable is PRELUDE THERAPEUTICS INC (PRLD) stock?

PRELUDE THERAPEUTICS INC (PRLD) has a profitability rating of 0 / 10.


Can you provide the financial health for PRLD stock?

The financial health rating of PRELUDE THERAPEUTICS INC (PRLD) is 5 / 10.